Procter & Gamble Hygiene and Health Care (500459) Q4 24/25 earnings summary

Executive summary

• Delivered balanced growth in a challenging macroeconomic environment, with 9-month sales of ₹3,374 crore and profit after tax of ₹637 crore, driven by innovation and a focused portfolio in feminine care and health care.

• Changed financial year to April–March, making FY 2024-25 a 9-month period, so figures are not directly comparable to the previous 12-month year.

• Continued investment in product superiority, productivity, and constructive disruption, with a strong focus on consumer-centric innovation and digital retail execution.

Financial highlights

• Revenue from operations for the 9-month period was ₹3,374 crore, compared to ₹4,206 crore in the previous 12-month year.

• Profit before tax was ₹862 crore; profit after tax was ₹637 crore.

• Earnings per share (EPS) for the period was ₹196.11.

• Operating profit margin stood at 26%.

• Cash generated from operations was ₹593 crore.

• Aggregate dividend for the year was ₹175 per share (interim ₹110, final ₹65).

Outlook and guidance

• Cautiously optimistic outlook for the future, with India expected to grow at 6.2% in 2025 and 6.3% in 2026, supported by private consumption and rural demand recovery.

• Company remains focused on integrated growth strategy and superior product offerings to sustain and improve performance.